Planned intervention: On Wednesday April 3rd 05:30 UTC Zenodo will be unavailable for up to 2-10 minutes to perform a storage cluster upgrade.
Published December 22, 2021 | Version v1
Journal article Open

FORMULATION OF BUPROPION HYDROCHLORIDE EXTENDED-RELEASE TABLET DOSAGE FORM

Description

The objective of the present investigation is to design and evaluate extended-release dosage form of bupropion hydrochloride and compare with innovator product (Wellbutrin extended-release tablets). Extended-release tablets were prepared by wet granulation method using HPMC and Microcrystalline Cellulose as matrixing agents. The granules prepared were shown satisfactory flow properties and compressibility. Prepared Granules were evaluated for Angle of repose, bulk density, tapped density, compressibility index, Hausner ratio. The granules shown satisfactory flow properties and compressibility. Tablets were tested for weight variation, thickness, hardness, friability and in vitro drug release as per official procedure. . Formulation of Extended-release tablet of bupropion hydrochloride as formulation batches F-1 and F-2 with a variation in the quantities of HPMC and Microcrystalline indicated that the formulation F-II be taken as an ideal or optimized formulation resembling the marketed product of Wellbutrin sustained release tablets for 10-hour release as it full fills all the requirements for sustained release tablet.

  • : Extended-release Tablets, bupropion hydrochloride, Hydroxy propyl methyl cellulose, Microcrystalline Cellulose, dissolution.

Files

33.Suresh Kumar-T.Divya.pdf

Files (1.1 MB)

Name Size Download all
md5:56e5122fa08b5662327f87a14f324c11
1.1 MB Preview Download